免费尼古丁贴片大规模分发计划的有效性:前性评估
Nancy Miller1, Thomas R Frieden, Sze Yan Liu
1New York City Department of Health and Mental Hygiene, New York, NY 10013, USA.
Lancet (London, England)
|June 1, 2005
概括
免费的尼古丁替代疗法 (NRT) 在纽约市显著改善了戒烟率. 这项公共卫生倡议展示了一种具有成本效益的方法,可以帮助各种人群戒烟.
科学领域:
- 公共卫生 公共卫生
- 控制烟草的控制方式
- 行为科学 行为科学
背景情况:
- 纽约市实施了增加的香烟税和无烟工作场所立法.
- 免费尼古丁替代疗法 (NRT) 的大规模分发由卫生部门和研究机构进行.
- 一项为期6个月的后续调查评估了该NRT计划在改善戒烟方面在人口层面取得的成功.
研究的目的:
- 评估基于人口的大规模尼古丁替代疗法 (NRT) 计划的有效性.
- 为了评估与对照组相比,NRT接受者的戒烟率.
- 确定提供免费NRT的公共卫生影响和成本效益.
主要方法:
- 34,090名符合条件的吸烟者接受了为期6周的尼古丁贴片疗程.
- 试图为NRT接受者进行简短的后续咨询电话.
- 通过对1305名随机抽取的NRT接受者和对照组进行调查,评估了6个月的吸烟状况.
主要成果:
- 与比较组 (6%) 相比,接受NRT的人的成功戒烟率 (33%) 显著更高.
- 在外国出生的个人,65岁以上的人和轻度吸烟者 (每天少于20支香烟) 中,戒烟成功率特别高.
- 据估计,有6038个成功戒烟者归因于NRT计划,每次戒烟的成本为464美元.
结论:
- 提供可访问的戒烟药物,如NRT,可以显著帮助各种人群戒烟.
- 提供免费NRT的公共卫生倡议可以有效地减少人口的吸烟率.
- 轻松获得NRT是加强各种人口群体戒烟努力的关键策略.
更多相关视频
09:04Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
08:36The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
Published on: April 19, 2024
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).